Epidemiology and Treatment of Trichomoniasis

  • Patricia KissingerEmail author
Intra-abdominal Infections, Hepatitis, and Gastroenteritis (T Steiner, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Intra-abdominal Infections, Hepatitis, and Gastroenteritis


Trichomonas vaginalis is the most common nonviral sexually transmitted infection (STI) in the world. It was once thought to be a nuisance STI, but it is now being recognized as an important source of reproductive morbidity and a facilitator of HIV transmission and acquisition, and thus it is an important public health problem. The prevalence of T. vaginalis varies greatly by geography and risk group, but is more common among persons of African descent and appears to increase with age, though this may be a screening phenomenon. Wet mount and culture are simple diagnostics, but have lower sensitivity than nucleic acid amplification techniques presently approved for women only. Single dose (2 g) metronidazole (MTZ) for both the index patient and their sexual partners is the preferred treatment. High rates of retest positivity are found after single-dose treatment which are likely due to clinical resistance rather than re-infection and/or drug resistance.


Trichomonas vaginalis Trichomoniasis Epidemiology Treatment 


Compliance with Ethics Guidelines

Conflict of Interest

Patricia Kissinger has no disclosures to report.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Harp DF, Chowdhury I. Trichomoniasis: evaluation to execution. Eur J Obstet Gynecol Reprod Biol. 2011;157(1):3–9.PubMedGoogle Scholar
  2. 2.
    Carlton JM et al. Draft genome sequence of the sexually transmitted pathogen Trichomonas vaginalis. Science. 2007;315(5809):207–12.PubMedCentralPubMedGoogle Scholar
  3. 3.
    Petrin D et al. Clinical and microbiological aspects of Trichomonas vaginalis. Clin Microbiol Rev. 1998;11(2):300–17.PubMedCentralPubMedGoogle Scholar
  4. 4.
    Krieger JN. Trichomoniasis in men: old issues and new data. Sex Transm Dis. 1995;22(2):83–96.PubMedGoogle Scholar
  5. 5.
    Burch TA, Rees CW, Reardon L. Diagnosis of Trichomonas vaginalis vaginitis. Am J Obstet Gynecol. 1959;77(2):309–13.PubMedGoogle Scholar
  6. 6.
    Charles SX. Epidemiology of trichomonas vaginalis (TV) in rural adolescent and juvenile children. J Trop Pediatr. 1991;37(2):90.PubMedGoogle Scholar
  7. 7.
    Adu-Sarkodie Y. Trichomonas vaginalis transmission in a family. Genitourin Med. 1995;71(3):199–200.PubMedCentralPubMedGoogle Scholar
  8. 8.
    Crucitti T et al. Non-sexual transmission of Trichomonas vaginalis in adolescent girls attending school in Ndola, Zambia. PLoS One. 2011;6(1):e16310.PubMedCentralPubMedGoogle Scholar
  9. 9.
    Sutton M et al. The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001–2004. Clin Infect Dis. 2007;45(10):1319–26.PubMedGoogle Scholar
  10. 10.
    Sena AC et al. Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention. Clin Infect Dis. 2007;44(1):13–22.PubMedGoogle Scholar
  11. 11.
    Wolner-Hanssen P et al. Clinical manifestations of vaginal trichomoniasis. JAMA. 1989;261(4):571–6.PubMedGoogle Scholar
  12. 12.
    Martinez-Garcia F et al. Protozoan infections in the male genital tract. J Urol. 1996;156(2 Pt 1):340–9.PubMedGoogle Scholar
  13. 13.
    Allsworth JE, Ratner JA, Peipert JF. Trichomoniasis and other sexually transmitted infections: results from the 2001–2004 National Health and Nutrition Examination Surveys. Sex Transm Dis. 2009;36(12):738–44.PubMedCentralPubMedGoogle Scholar
  14. 14.
    Silver BJ et al. Trichomonas vaginalis as a cause of perinatal morbidity: a systematic review and meta-analysis. Sex Transm Dis. 2014;41(6):369–76.PubMedGoogle Scholar
  15. 15.
    Mann JR et al. Trichomoniasis in pregnancy and mental retardation in children. Ann Epidemiol. 2009;19(12):891–9.PubMedGoogle Scholar
  16. 16.
    Schwandt A, Williams C, Beigi RH. Perinatal transmission of Trichomonas vaginalis: a case report. J Reprod Med. 2008;53(1):59–61.PubMedGoogle Scholar
  17. 17.
    Carter JE, Whithaus KC. Neonatal respiratory tract involvement by Trichomonas vaginalis: a case report and review of the literature. Am J Trop Med Hyg. 2008;78(1):17–9.PubMedGoogle Scholar
  18. 18.
    Temesvari P et al. Demonstration of Trichomonas vaginalis in tracheal aspirates in infants with early respiratory failure. J Matern Fetal Neonatal Med. 2002;11(5):347–9.PubMedGoogle Scholar
  19. 19.•
    Kissinger P, Adamski A. Trichomoniasis and HIV interactions: a review. Sex Transm Infect. 2013;89(6):426–33. This study is a comprehensive review of the how T. vaginalis influences both transmission and acquisition of HIV.PubMedCentralPubMedGoogle Scholar
  20. 20.
    Sardana S et al. Epidemiologic analysis of Trichomonas vaginalis infection in inflammatory smears. Acta Cytol. 1994;38(5):693–7.PubMedGoogle Scholar
  21. 21.
    Guenthner PC, Secor WE, Dezzutti CS. Trichomonas vaginalis-induced epithelial monolayer disruption and human immunodeficiency virus type 1 (HIV-1) replication: implications for the sexual transmission of HIV-1. Infect Immun. 2005;73(7):4155–60.PubMedCentralPubMedGoogle Scholar
  22. 22.
    Moodley P, Connolly C, Sturm AW. Interrelationships among human immunodeficiency virus type 1 infection, bacterial vaginosis, trichomoniasis, and the presence of yeasts. J Infect Dis. 2002;185(1):69–73.PubMedGoogle Scholar
  23. 23.
    van de Wijgert JH et al. Disentangling contributions of reproductive tract infections to HIV acquisition in African women. Sex Transm Dis. 2009;36(6):357–64.PubMedGoogle Scholar
  24. 24.
    Sorvillo F, Kerndt P. Trichomonas vaginalis and amplification of HIV-1 transmission. Lancet. 1998;351(9097):213–4.PubMedGoogle Scholar
  25. 25.
    Chesson HW, Blandford JM, Pinkerton SD. Estimates of the annual number and cost of new HIV infections among women attributable to trichomoniasis in the United States. Sex Transm Dis. 2004;31(9):547–51.PubMedGoogle Scholar
  26. 26.
    McClelland RS. Trichomonas vaginalis infection: can we afford to do nothing? J Infect Dis. 2008;197(4):487–9.PubMedGoogle Scholar
  27. 27.
    Price MA et al. The cost-effectiveness of treating male trichomoniasis to avert HIV transmission in men seeking sexually transmitted disease care in Malawi. J Acquir Immune Defic Syndr. 2006;43(2):202–9.PubMedGoogle Scholar
  28. 28.
    Sorvillo F et al. Trichomonas vaginalis, HIV, and African-Americans. Emerg Infect Dis. 2001;7(6):927–32.PubMedCentralPubMedGoogle Scholar
  29. 29.
    Price MA et al. Addition of treatment for trichomoniasis to syndromic management of urethritis in Malawi: a randomized clinical trial. Sex Transm Dis. 2003;30(6):516–22.PubMedGoogle Scholar
  30. 30.
    Wang CC et al. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis. 2001;183(7):1017–22.PubMedGoogle Scholar
  31. 31.
    Kissinger P et al. Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding. Sex Transm Dis. 2009;36(1):11–6.PubMedCentralPubMedGoogle Scholar
  32. 32.
    Boselli F et al. Prevalence and determinants of genital shedding of herpes simplex virus among women attending Italian colposcopy clinics. Eur J Obstet Gynecol Reprod Biol. 2005;118(1):86–90.PubMedGoogle Scholar
  33. 33.
    Gottlieb SL et al. Incidence of herpes simplex virus type 2 infection in 5 sexually transmitted disease (STD) clinics and the effect of HIV/STD risk-reduction counseling. J Infect Dis. 2004;190(6):1059–67.PubMedGoogle Scholar
  34. 34.
    Zhang ZF, Begg CB. Is Trichomonas vaginalis a cause of cervical neoplasia? Results from a combined analysis of 24 studies. Int J Epidemiol. 1994;23(4):682–90.PubMedGoogle Scholar
  35. 35.
    Viikki M et al. Gynaecological infections as risk determinants of subsequent cervical neoplasia. Acta Oncol. 2000;39(1):71–5.PubMedGoogle Scholar
  36. 36.
    Roeters AM et al. Inflammatory events as detected in cervical smears and squamous intraepithelial lesions. Diagn Cytopathol. 2010;38(2):85–93.PubMedGoogle Scholar
  37. 37.
    Depuydt CE et al. Epidemiology of Trichomonas vaginalis and human papillomavirus infection detected by real-time PCR in Flanders. Gynecol Obstet Invest. 2010;70(4):273–80.PubMedGoogle Scholar
  38. 38.
    Li C et al. A population-based study on the risks of cervical lesion and human papillomavirus infection among women in Beijing, People’s Republic of China. Cancer Epidemiol Biomarkers Prev. 2010;19(10):2655–64.PubMedGoogle Scholar
  39. 39.
    Yap EH et al. Serum antibodies to Trichomonas vaginalis in invasive cervical cancer patients. Genitourin Med. 1995;71(6):402–4.PubMedCentralPubMedGoogle Scholar
  40. 40.
    Sutcliffe S et al. Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(5):939–45.PubMedGoogle Scholar
  41. 41.
    Sutcliffe S et al. Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial. Int J Cancer. 2009;124(9):2082–7.PubMedCentralPubMedGoogle Scholar
  42. 42.
    Wiese W et al. A meta-analysis of the Papanicolaou smear and wet mount for the diagnosis of vaginal trichomoniasis. Am J Med. 2000;108(4):301–8.PubMedGoogle Scholar
  43. 43.
    Peterman TA et al. Persistent, undetected Trichomonas vaginalis infections? Clin Infect Dis. 2009;48(2):259–60.PubMedGoogle Scholar
  44. 44.
    Gatski M et al. Patient-delivered partner treatment and Trichomonas vaginalis repeat infection among human immunodeficiency virus-infected women. Sex Transm Dis. 2010;37(8):502–5.PubMedCentralPubMedGoogle Scholar
  45. 45.
    Van Der Pol B, Kraft CS, Williams JA. Use of an adaptation of a commercially available PCR assay aimed at diagnosis of chlamydia and gonorrhea to detect Trichomonas vaginalis in urogenital specimens. J Clin Microbiol. 2006;44(2):366–73.Google Scholar
  46. 46.
    Nye MB, Schwebke JR, B.A. Body. Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women. Am J Obstet Gynecol. 2009;200(2):188 e1-7.PubMedGoogle Scholar
  47. 47.
    Huppert JS et al. Urinary symptoms in adolescent females: STI or UTI? J Adolesc Health. 2007;40(5):418–24.PubMedCentralPubMedGoogle Scholar
  48. 48.
    Andrea SB, Chapin KC. Comparison of Aptima Trichomonas vaginalis transcription-mediated amplification assay and BD affirm VPIII for detection of T. vaginalis in symptomatic women: performance parameters and epidemiological implications. J Clin Microbiol. 2011;49(3):866–9.PubMedCentralPubMedGoogle Scholar
  49. 49.
    Huppert JS et al. Rapid antigen testing compares favorably with transcription-mediated amplification assay for the detection of Trichomonas vaginalis in young women. Clin Infect Dis. 2007;45(2):194–8.PubMedGoogle Scholar
  50. 50.
    Van Der Pol B et al. Prevalence, incidence, natural history, and response to treatment of Trichomonas vaginalis infection among adolescent women. J Infect Dis. 2005;192(12):2039–44.Google Scholar
  51. 51.
    World Health Organization, W. Prevalence and incidence of selected sexually transmitted infections, Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis and Trichomonas vaginalis: methods and results used by WHO to generate 2005 estimates. W. Press, Editor 2011: Geneva, Switzerland.Google Scholar
  52. 52.
    Khan MS et al. HIV, STI prevalence and risk behaviours among women selling sex in Lahore, Pakistan. BMC Infect Dis. 2011;11:119.PubMedCentralPubMedGoogle Scholar
  53. 53.
    Roth AM et al. Changing sexually transmitted infection screening protocol will result in improved case finding for trichomonas vaginalis among high-risk female populations. Sex Transm Dis. 2011;38(5):398–400.PubMedGoogle Scholar
  54. 54.
    Freeman AH et al. Prevalence and correlates of Trichomonas vaginalis among incarcerated persons assessed using a highly sensitive molecular assay. Sex Transm Dis. 2010;37(3):165–8.PubMedGoogle Scholar
  55. 55.
    Hobbs MM et al. Methods for detection of Trichomonas vaginalis in the male partners of infected women: implications for control of trichomoniasis. J Clin Microbiol. 2006;44(11):3994–9.PubMedCentralPubMedGoogle Scholar
  56. 56.
    Vallely A et al. High prevalence and incidence of HIV, sexually transmissible infections and penile foreskin cutting among sexual health clinic attendees in Papua New Guinea. Sex Health. 2014;11(1):58–66.PubMedGoogle Scholar
  57. 57.
    Soto RJ et al. Sentinel surveillance of sexually transmitted infections/HIV and risk behaviors in vulnerable populations in 5 Central American countries. J Acquir Immune Defic Syndr. 2007;46(1):101–11.PubMedGoogle Scholar
  58. 58.
    Meites E et al. Trichomonas vaginalis in selected U.S. sexually transmitted disease clinics: testing, screening, and prevalence. Sex Transm Dis. 2013;40(11):865–9.PubMedGoogle Scholar
  59. 59.
    Miller WC et al. The prevalence of trichomoniasis in young adults in the United States. Sex Transm Dis. 2005;32(10):593–8.PubMedGoogle Scholar
  60. 60.
    Gregson S et al. A rural HIV epidemic in Zimbabwe? Findings from a population-based survey. Int J STD AIDS. 2001;12(3):189–96.PubMedGoogle Scholar
  61. 61.
    Klinger EV et al. A Community-based study of risk factors for Trichomonas vaginalis infection among women and their male partners in Moshi urban district, northern Tanzania. Sex Transm Dis. 2006;33(12):712–8.PubMedGoogle Scholar
  62. 62.
    Lan PT et al. Reproductive tract infections including sexually transmitted infections: a population-based study of women of reproductive age in a rural district of Vietnam. Sex Transm Infect. 2008;84(2):126–32.PubMedGoogle Scholar
  63. 63.
    Huang HC et al. Preparation of monoclonal antibodies against the adhesion protein 33 of Trichomonas vaginalis. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2007;25(2):97–100. 105.PubMedGoogle Scholar
  64. 64.
    Johnston VJ, Mabey DC. Global epidemiology and control of Trichomonas vaginalis. Curr Opin Infect Dis. 2008;21(1):56–64.PubMedGoogle Scholar
  65. 65.
    Paz-Bailey G et al. High rates of STD and sexual risk behaviors among Garifunas in Honduras. J Acquir Immune Defic Syndr. 2009;51 Suppl 1:S26–34.PubMedGoogle Scholar
  66. 66.
    Shafir SC, Sorvillo FJ, Smith L. Current issues and considerations regarding trichomoniasis and human immunodeficiency virus in African-Americans. Clin Microbiol Rev. 2009;22(1):37–45. Table of Contents.PubMedCentralPubMedGoogle Scholar
  67. 67.
    Rathod SD et al. Bacterial vaginosis and risk for Trichomonas vaginalis infection: a longitudinal analysis. Sex Transm Dis. 2011;38(9):882–6.PubMedCentralPubMedGoogle Scholar
  68. 68.
    Swartzendruber A et al. Correlates of incident Trichomonas vaginalis infections among African American female adolescents. Sex Transm Dis. 2014;41(4):240–5.PubMedCentralPubMedGoogle Scholar
  69. 69.
    Krashin JW et al. Trichomonas vaginalis prevalence, incidence, risk factors and antibiotic-resistance in an adolescent population. Sex Transm Dis. 2010;37(7):440–4.PubMedGoogle Scholar
  70. 70.
    Cotch MF et al. Demographic and behavioral predictors of Trichomonas vaginalis infection among pregnant women. The Vaginal Infections and Prematurity Study Group. Obstet Gynecol. 1991;78(6):1087–92.PubMedGoogle Scholar
  71. 71.
    Franklin TL, Monif GR. Trichomonas vaginalis and bacterial vaginosis. Coexistence in vaginal wet mount preparations from pregnant women. J Reprod Med. 2000;45(2):131–4.PubMedGoogle Scholar
  72. 72.
    Rosenberg MJ et al. Barrier contraceptives and sexually transmitted diseases in women: a comparison of female-dependent methods and condoms. Am J Public Health. 1992;82(5):669–74.PubMedCentralPubMedGoogle Scholar
  73. 73.
    Peterman TA et al. High incidence of new sexually transmitted infections in the year following a sexually transmitted infection: a case for rescreening. Ann Intern Med. 2006;145(8):564–72.PubMedGoogle Scholar
  74. 74.
    Pabst KM et al. Disease prevalence among women attending a sexually transmitted disease clinic varies with reason for visit. Sex Transm Dis. 1992;19(2):88–91.PubMedGoogle Scholar
  75. 75.
    Kurth A et al. Performance of a new, rapid assay for detection of Trichomonas vaginalis. J Clin Microbiol. 2004;42(7):2940–3.PubMedCentralPubMedGoogle Scholar
  76. 76.
    DeHovitz JA et al. Sexually transmitted diseases, sexual behavior, and cocaine use in inner-city women. Am J Epidemiol. 1994;140(12):1125–34.PubMedGoogle Scholar
  77. 77.
    Miller M et al. Factors associated with the prevalence and incidence of Trichomonas vaginalis infection among African American women in New York City who use drugs. J Infect Dis. 2008;197(4):503–9.PubMedGoogle Scholar
  78. 78.
    Shuter J et al. Rates of and risk factors for trichomoniasis among pregnant inmates in New York City. Sex Transm Dis. 1998;25(6):303–7.PubMedGoogle Scholar
  79. 79.
    Wendel KA, Workowski KA. Trichomoniasis: challenges to appropriate management. Clin Infect Dis. 2007;44 Suppl 3:S123–9.PubMedGoogle Scholar
  80. 80.
    Cudmore SL et al. Treatment of infections caused by metronidazole-resistant Trichomonas vaginalis. Clin Microbiol Rev. 2004;17(4):783–93. table of contents.PubMedCentralPubMedGoogle Scholar
  81. 81.
    Burtin P et al. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol. 1995;172(2 Pt 1):525–9.PubMedGoogle Scholar
  82. 82.
    Caro-Paton T et al. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol. 1997;44(2):179–82.PubMedCentralPubMedGoogle Scholar
  83. 83.
    Csonka GW. Trichomonal vaginitis treated with one dose of metronidazole. Br J Vener Dis. 1971;47(6):456–8.PubMedCentralPubMedGoogle Scholar
  84. 84.
    Hager WD et al. Metronidazole for vaginal trichomoniasis. Seven-day vs single-dose regimens. JAMA. 1980;244(11):1219–20.PubMedGoogle Scholar
  85. 85.
    Schwebke JR, Desmond RA. Tinidazole vs metronidazole for the treatment of bacterial vaginosis. Am J Obstet Gynecol. 2011;204(3):211 e1-6.PubMedGoogle Scholar
  86. 86.•
    Workowski KA, Berman SM. Centers for Disease Control and prevention sexually transmitted disease treatment guidelines. Clin Infect Dis. 2011;53 Suppl 3:S59–63. This study described state of the art treatment recommendations for T. vaginalis by the Centers for Disease Control and Prevention.PubMedGoogle Scholar
  87. 87.
    Kissinger P et al. A randomized treatment trial: single versus 7 day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women. J Acquir Immune Defic Syndr. 2011;55(5):565–71.Google Scholar
  88. 88.
    Gatski M et al. The influence of bacterial vaginosis on the response to Trichomonas vaginalis treatment among HIV-infected women. Sex Transm Infect. 2011;87(3):205–8.PubMedCentralPubMedGoogle Scholar
  89. 89.
    Adamski A et al. The influence of ART on the treatment of Trichomonas vaginalis among HIV-infected women. Clin Infect Dis. 2014;59(6):883–7.PubMedGoogle Scholar
  90. 90.
    Balkus JE et al. A prospective cohort study comparing the effect of single-dose 2g metronidazole on Trichomonas vaginalis infection in HIV-seropositive versus HIV-seronegative women. Sex Transm Dis. 2013;40(6):499–505.PubMedCentralPubMedGoogle Scholar
  91. 91.
    Kissinger P et al. Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women. Clin Infect Dis. 2008;46(7):994–9.PubMedGoogle Scholar
  92. 92.
    Kissinger P et al. Patient-delivered partner treatment for Trichomonas vaginalis infection: a randomized controlled trial. Sex Transm Dis. 2006;33(7):445–50.PubMedGoogle Scholar
  93. 93.
    Spence MR et al. The minimum single oral metronidazole dose for treating trichomoniasis: a randomized, blinded study. Obstet Gynecol. 1997;89(5 Pt 1):699–703.PubMedGoogle Scholar
  94. 94.•
    Forna F, Gulmezoglu AM. Interventions for treating trichomoniasis in women. Cochrane Datab Syst Rev. 2003(2): CD000218. This meta-analysis described the limitations of the present recommendations for treatment of T. vaginalis.Google Scholar
  95. 95.
    Schwebke JR, Barrientes FJ. Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole. Antimicrob Agents Chemother. 2006;50(12):4209–10.PubMedCentralPubMedGoogle Scholar
  96. 96.
    Perez S et al. Prevalence of 5-nitroimidazole-resistant trichomonas vaginalis in Oviedo. Spain Sex Transm Dis. 2001;28(2):115–6.Google Scholar
  97. 97.
    Schmid G et al. Prevalence of metronidazole-resistant Trichomonas vaginalis in a gynecology clinic. J Reprod Med. 2001;46(6):545–9.PubMedGoogle Scholar
  98. 98.
    Magnus M et al. Trichomonas vaginalis among HIV-Infected women: are immune status or protease inhibitor use associated with subsequent T. vaginalis positivity? Sex Transm Dis. 2003;30(11):839–43.PubMedGoogle Scholar
  99. 99.
    Niccolai LM et al. Incidence and predictors of reinfection with Trichomonas vaginalis in HIV-infected women. Sex Transm Dis. 2000;27(5):284–8.PubMedGoogle Scholar
  100. 100.
    Lyng J, Christensen J. A double-blind study of the value of treatment with a single dose tinidazole of partners to females with trichomoniasis. Acta Obstet Gynecol Scand. 1981;60(2):199–201.PubMedGoogle Scholar
  101. 101.
    Schwebke JR, Desmond RA. A randomized controlled trial of partner notification methods for prevention of trichomoniasis in women. Sex Transm Dis. 2010;37(6):392–6.PubMedGoogle Scholar
  102. 102.
    Funkhouser E, Hayes TD, Vermund SH. Vaginal douching practices among women attending a university in the southern United States. J Am Coll Health. 2002;50(4):177–82.PubMedGoogle Scholar
  103. 103.
    Plitt SS et al. Prevalence and correlates of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis infections, and bacterial vaginosis among a cohort of young injection drug users in Baltimore, Maryland. Sex Transm Dis. 2005;32(7):446–53.PubMedGoogle Scholar
  104. 104.
    Doherty IA, Schoenbach VJ, Adimora AA. Condom use and duration of concurrent partnerships among men in the United States. Sex Transm Dis. 2009;36(5):265–72.PubMedCentralPubMedGoogle Scholar
  105. 105.
    Sewankambo N et al. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet. 1997;350(9077):546–50.PubMedGoogle Scholar
  106. 106.
    Thomason JL et al. Comparison of four methods to detect Trichomonas vaginalis. J Clin Microbiol. 1988;26(9):1869–70.PubMedCentralPubMedGoogle Scholar
  107. 107.
    Demirezen S, Kaya D, Beksac S. Cytologic findings in pap smears with Actinomyces-like organisms. Acta Cytol. 2005;49(3):257–61.PubMedGoogle Scholar
  108. 108.
    Heller DS, Maslyak S, Skurnick J. Is the presence of Trichomonas on a Pap smear associated with an increased incidence of bacterial vaginosis? J Low Genit Tract Dis. 2006;10(3):137–9.PubMedGoogle Scholar
  109. 109.
    Gatski M et al. Co-occurrence of Trichomonas vaginalis and bacterial vaginosis among HIV-positive women. Sex Transm Dis. 2011;38(3):163–6.PubMedCentralPubMedGoogle Scholar
  110. 110.
    Hillier SL et al. Characteristics of three vaginal flora patterns assessed by gram stain among pregnant women. Vaginal Infections and Prematurity Study Group. Am J Obstet Gynecol. 1992;166(3):938–44.PubMedGoogle Scholar
  111. 111.
    Martin DH et al. Unique vaginal microbiota that includes an unknown mycoplasma-like organism is associated with Trichomonas vaginalis infection. J Infect Dis. 2013;207(12):1922–31.PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.School of Public Health and Tropical MedicineTulane UniversityNew OrleansUSA

Personalised recommendations